An official website of the United States government
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Trial Status: active
A first in human study to evaluate the safety and preliminary antitumor activity of
BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or
metastatic KRAS mutant solid tumors.
Inclusion Criteria
Histologically documented locally advanced and unresectable or metastatic NSCLC, PDAC, CRC, or other solid tumor with KRAS G12A, G12C, G12D, G12S, or G12V mutation
Measurable disease by RECIST v1.1
Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1
Life expectancy >24 weeks
Adequate organ function
Exclusion Criteria
Malignancy within the last 2 years as specified in the protocol
Untreated brain metastases Other inclusion/exclusion criteria are specified in the protocol.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT06917079.
Locations matching your search criteria
United States
Arizona
Scottsdale
Mayo Clinic in Arizona
Status: Approved
Name Not Available
California
La Jolla
UC San Diego Moores Cancer Center
Status: Active
Name Not Available
Sacramento
University of California Davis Comprehensive Cancer Center
